Hainan Haiyao announced that Haikou Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently obtained the “Drug Registration Certificate” for injectable esaconazole sulfate approved and issued by the State Drug Administration. The specification is 200mg, which is suitable for treating aggressive aspergillosis and invasive trichomoniasis in adults and children aged 1 year and above.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.